Brigid Bio

Brigid Bio is a biotech spin-out from the University of Aberdeen, developing first in class antibody-based drugs as safer and efficacious treatment solutions for high-risk and drug resistant fungal infections. We have developed a unique and proprietary drug discovery platform and identified key cell wall markers as novel drug targets which are fungal pathogen specific and critical for infection and resistance. Our lead human monoclonal antibodies to these targets have proven efficacy in a ‘clinically predictive’ in vivo infection model. Brigid Bio is supported by the Scottish Enterprise High Growth Spinout Programme and led by a team of globally recognized scientific expertise and commercial experience.